Haematology registrar, Clinical Haematology, Auckland City Hospital, Auckland, New Zealand.
Clinical Nurse Specialist, Clinical Haematology, Auckland City Hospital, Auckland, New Zealand.
N Z Med J. 2023 Mar 24;136(1572):10-18. doi: 10.26635/6965.5952.
Acute lymphoblastic leukaemia/lymphoma (ALL) is a rare disease that requires an intensive chemotherapy regimen for successful treatment. This is a single-centre retrospective audit to assess the treatment outcomes in the largest ALL centre in New Zealand.
Data such as survival and adverse events of patients with de novo ALL referred to Auckland City Hospital for treatment were included in this audit. Sub-group analyses were also performed.
Sixty-five patients aged from 18 upwards with ALL were included in this audit. The median survival of all patients was 37.6 months. Adolescent and young adults (AYA) treated on the COG (paediatric) protocols had a mean survival of 48.3 months (median not reached), while adults treated with the UKALL14 protocol had a median survival of 37.6 months. In the UKALL14 sub-group, Māori/Pacific Islanders had an inferior EFS that was statistically significant.
Overall AYA outcomes are comparable to international standards. Our adult outcomes may be poorer than the original UKALL14 trial, with Māori/Pacific Island patients having shorter survival.
急性淋巴细胞白血病/淋巴瘤（ALL）是一种罕见疾病，需要强化化疗方案才能成功治疗。这是一项单中心回顾性审计，旨在评估新西兰最大 ALL 中心的治疗结果。
本审计纳入了转诊至奥克兰市医院治疗的初治 ALL 患者的生存和不良事件等数据。还进行了亚组分析。
本审计纳入了 65 名年龄在 18 岁及以上的 ALL 患者。所有患者的中位总生存期为 37.6 个月。接受 COG（儿科）方案治疗的青少年和年轻成人（AYA）的平均总生存期为 48.3 个月（未达到中位生存期），而接受 UKALL14 方案治疗的成年人的中位总生存期为 37.6 个月。在 UKALL14 亚组中，毛利/太平洋岛民的 EFS 较差，具有统计学意义。
总体而言，AYA 的结果与国际标准相当。我们的成人结果可能不如原始的 UKALL14 试验，毛利/太平洋岛民患者的生存期更短。
